Molecular Biology of the Cell, volume 25, issue 18, pages 2677-2681

How Taxol/paclitaxel kills cancer cells

Weaver Beth A. 1
1
 
Department of Cell and Regenerative Biology and Carbone Cancer Center, University of Wisconsin, Madison, WI 53705
Publication typeJournal Article
Publication date2014-09-15
Quartile SCImago
Q1
Quartile WOS
Q3
Impact factor3.3
ISSN10591524, 19394586
Molecular Biology
Cell Biology
Abstract

Taxol (generic name paclitaxel) is a microtubule-stabilizing drug that is approved by the Food and Drug Administration for the treatment of ovarian, breast, and lung cancer, as well as Kaposi's sarcoma. It is used off-label to treat gastroesophageal, endometrial, cervical, prostate, and head and neck cancers, in addition to sarcoma, lymphoma, and leukemia. Paclitaxel has long been recognized to induce mitotic arrest, which leads to cell death in a subset of the arrested population. However, recent evidence demonstrates that intratumoral concentrations of paclitaxel are too low to cause mitotic arrest and result in multipolar divisions instead. It is hoped that this insight can now be used to develop a biomarker to identify the ∼50% of patients that will benefit from paclitaxel therapy. Here I discuss the history of paclitaxel and our recently evolved understanding of its mechanism of action.

Citations by journals

5
10
15
20
25
30
35
Molecules
Molecules, 31, 3.29%
Molecules
31 publications, 3.29%
Cancers
Cancers, 20, 2.12%
Cancers
20 publications, 2.12%
Scientific Reports
Scientific Reports, 20, 2.12%
Scientific Reports
20 publications, 2.12%
International Journal of Molecular Sciences
International Journal of Molecular Sciences, 14, 1.48%
International Journal of Molecular Sciences
14 publications, 1.48%
Frontiers in Pharmacology
Frontiers in Pharmacology, 13, 1.38%
Frontiers in Pharmacology
13 publications, 1.38%
Biomedicine and Pharmacotherapy
Biomedicine and Pharmacotherapy, 13, 1.38%
Biomedicine and Pharmacotherapy
13 publications, 1.38%
Oncotarget
Oncotarget, 12, 1.27%
Oncotarget
12 publications, 1.27%
Frontiers in Oncology
Frontiers in Oncology, 11, 1.17%
Frontiers in Oncology
11 publications, 1.17%
Oncology Letters
Oncology Letters, 10, 1.06%
Oncology Letters
10 publications, 1.06%
Pharmaceutics
Pharmaceutics, 9, 0.95%
Pharmaceutics
9 publications, 0.95%
Biomedicines
Biomedicines, 9, 0.95%
Biomedicines
9 publications, 0.95%
PLoS ONE
PLoS ONE, 9, 0.95%
PLoS ONE
9 publications, 0.95%
Oncology Reports
Oncology Reports, 8, 0.85%
Oncology Reports
8 publications, 0.85%
Nature Communications
Nature Communications, 7, 0.74%
Nature Communications
7 publications, 0.74%
International Journal of Nanomedicine
International Journal of Nanomedicine, 6, 0.64%
International Journal of Nanomedicine
6 publications, 0.64%
ACS applied materials & interfaces
ACS applied materials & interfaces, 5, 0.53%
ACS applied materials & interfaces
5 publications, 0.53%
Journal of Controlled Release
Journal of Controlled Release, 5, 0.53%
Journal of Controlled Release
5 publications, 0.53%
Journal of Medicinal Chemistry
Journal of Medicinal Chemistry, 5, 0.53%
Journal of Medicinal Chemistry
5 publications, 0.53%
Cells
Cells, 5, 0.53%
Cells
5 publications, 0.53%
Cell Death and Disease
Cell Death and Disease, 5, 0.53%
Cell Death and Disease
5 publications, 0.53%
Bioorganic Chemistry
Bioorganic Chemistry, 5, 0.53%
Bioorganic Chemistry
5 publications, 0.53%
Frontiers in Cell and Developmental Biology
Frontiers in Cell and Developmental Biology, 4, 0.42%
Frontiers in Cell and Developmental Biology
4 publications, 0.42%
Pharmaceuticals
Pharmaceuticals, 4, 0.42%
Pharmaceuticals
4 publications, 0.42%
Cancer Chemotherapy and Pharmacology
Cancer Chemotherapy and Pharmacology, 4, 0.42%
Cancer Chemotherapy and Pharmacology
4 publications, 0.42%
Chemico-Biological Interactions
Chemico-Biological Interactions, 4, 0.42%
Chemico-Biological Interactions
4 publications, 0.42%
European Journal of Pharmacology
European Journal of Pharmacology, 4, 0.42%
European Journal of Pharmacology
4 publications, 0.42%
Cancer Letters
Cancer Letters, 4, 0.42%
Cancer Letters
4 publications, 0.42%
European Journal of Medicinal Chemistry
European Journal of Medicinal Chemistry, 4, 0.42%
European Journal of Medicinal Chemistry
4 publications, 0.42%
Advanced healthcare materials
Advanced healthcare materials, 4, 0.42%
Advanced healthcare materials
4 publications, 0.42%
5
10
15
20
25
30
35

Citations by publishers

20
40
60
80
100
120
140
160
Springer Nature
Springer Nature, 159, 16.86%
Springer Nature
159 publications, 16.86%
Elsevier
Elsevier, 155, 16.44%
Elsevier
155 publications, 16.44%
Multidisciplinary Digital Publishing Institute (MDPI)
Multidisciplinary Digital Publishing Institute (MDPI), 121, 12.83%
Multidisciplinary Digital Publishing Institute (MDPI)
121 publications, 12.83%
Wiley
Wiley, 56, 5.94%
Wiley
56 publications, 5.94%
Frontiers Media S.A.
Frontiers Media S.A., 45, 4.77%
Frontiers Media S.A.
45 publications, 4.77%
American Chemical Society (ACS)
American Chemical Society (ACS), 41, 4.35%
American Chemical Society (ACS)
41 publications, 4.35%
Taylor & Francis
Taylor & Francis, 41, 4.35%
Taylor & Francis
41 publications, 4.35%
Spandidos Publications
Spandidos Publications, 28, 2.97%
Spandidos Publications
28 publications, 2.97%
Bentham Science
Bentham Science, 13, 1.38%
Bentham Science
13 publications, 1.38%
Impact Journals
Impact Journals, 13, 1.38%
Impact Journals
13 publications, 1.38%
Royal Society of Chemistry (RSC)
Royal Society of Chemistry (RSC), 11, 1.17%
Royal Society of Chemistry (RSC)
11 publications, 1.17%
Dove Medical Press
Dove Medical Press, 10, 1.06%
Dove Medical Press
10 publications, 1.06%
Public Library of Science (PLoS)
Public Library of Science (PLoS), 10, 1.06%
Public Library of Science (PLoS)
10 publications, 1.06%
American Association for Cancer Research (AACR)
American Association for Cancer Research (AACR), 10, 1.06%
American Association for Cancer Research (AACR)
10 publications, 1.06%
SAGE
SAGE, 9, 0.95%
SAGE
9 publications, 0.95%
Hindawi Limited
Hindawi Limited, 9, 0.95%
Hindawi Limited
9 publications, 0.95%
Oxford University Press
Oxford University Press, 7, 0.74%
Oxford University Press
7 publications, 0.74%
Walter de Gruyter
Walter de Gruyter, 6, 0.64%
Walter de Gruyter
6 publications, 0.64%
Future Medicine
Future Medicine, 5, 0.53%
Future Medicine
5 publications, 0.53%
Wolters Kluwer Health
Wolters Kluwer Health, 5, 0.53%
Wolters Kluwer Health
5 publications, 0.53%
Mary Ann Liebert
Mary Ann Liebert, 4, 0.42%
Mary Ann Liebert
4 publications, 0.42%
American Scientific Publishers
American Scientific Publishers, 3, 0.32%
American Scientific Publishers
3 publications, 0.32%
Bioscientifica
Bioscientifica, 3, 0.32%
Bioscientifica
3 publications, 0.32%
The Company of Biologists
The Company of Biologists, 3, 0.32%
The Company of Biologists
3 publications, 0.32%
Proceedings of the National Academy of Sciences (PNAS)
Proceedings of the National Academy of Sciences (PNAS), 3, 0.32%
Proceedings of the National Academy of Sciences (PNAS)
3 publications, 0.32%
eLife Sciences Publications
eLife Sciences Publications, 3, 0.32%
eLife Sciences Publications
3 publications, 0.32%
EMBO press
EMBO press, 2, 0.21%
EMBO press
2 publications, 0.21%
The Endocrine Society
The Endocrine Society, 2, 0.21%
The Endocrine Society
2 publications, 0.21%
The Royal Society
The Royal Society, 2, 0.21%
The Royal Society
2 publications, 0.21%
20
40
60
80
100
120
140
160
  • We do not take into account publications that without a DOI.
  • Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
  • Statistics recalculated weekly.
Metrics
Share
Cite this
GOST |
Cite this
GOST Copy
Weaver B. A. How Taxol/paclitaxel kills cancer cells // Molecular Biology of the Cell. 2014. Vol. 25. No. 18. pp. 2677-2681.
GOST all authors (up to 50) Copy
Weaver B. A. How Taxol/paclitaxel kills cancer cells // Molecular Biology of the Cell. 2014. Vol. 25. No. 18. pp. 2677-2681.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1091/mbc.e14-04-0916
UR - https://doi.org/10.1091%2Fmbc.e14-04-0916
TI - How Taxol/paclitaxel kills cancer cells
T2 - Molecular Biology of the Cell
AU - Weaver, Beth A.
PY - 2014
DA - 2014/09/15 00:00:00
PB - American Society for Cell Biology (ASCB)
SP - 2677-2681
IS - 18
VL - 25
PMID - 25213191
SN - 1059-1524
SN - 1939-4586
ER -
BibTex |
Cite this
BibTex Copy
@article{2014_Weaver
author = {Beth A. Weaver},
title = {How Taxol/paclitaxel kills cancer cells},
journal = {Molecular Biology of the Cell},
year = {2014},
volume = {25},
publisher = {American Society for Cell Biology (ASCB)},
month = {sep},
url = {https://doi.org/10.1091%2Fmbc.e14-04-0916},
number = {18},
pages = {2677--2681},
doi = {10.1091/mbc.e14-04-0916}
}
MLA
Cite this
MLA Copy
Weaver, Beth A.. “How Taxol/paclitaxel kills cancer cells.” Molecular Biology of the Cell, vol. 25, no. 18, Sep. 2014, pp. 2677-2681. https://doi.org/10.1091%2Fmbc.e14-04-0916.
Found error?